
Discovery analysis
Traits
Samples
T2D, Obesity
Waist circumference
Fasting glucose
Fasting insulin
2-h glucose
CoLaus
sequenced
(n = 2086)
CoLaus
imputed
(n = 3539)
Obesity
Waist circumference
Fasting glucose
Fasting insulin
GEMs
sequenced
(n = 1579)
BMI
Individuals with BMI
sequenced (n = 11,806)
Variants with suggestive associations:
p < 0.001 or in a target of interest to GSK
with p < 0.05 are listed in Table 1
Targeted genotyping follow-up analysis
Traits
Fasting glucose, 2 hour glucose, T2D, BMI
Samples
Ely (g)
(n = 1722)
LOLIPOP (g)
(n = 6565)
EPIC-Norfolk (g)
(n = 25,313)
ADDITION-Ely (g)
(n = 932 T2D cases - 1487 controls)
Fenland (g)
(n = 6379)
GenOA (i)
(n=129 cases, 1501 controls)
In silico follow-up analysis
Traits
Fasting glucose, 2 hour glucose, T2D, BMI
Samples
MAGIC
(FG: n = 20,077;
2h glucose: n = 15,234)
CHARGE Exome Chip analyses
(FG n = 49,838;
T2D cases = 9524,
n controls = 60,718;
BMI n = 68,978)
Combined Analysis: Meta-analysis of discovery, follow-up and in silico follow-up analyses